JP2018510191A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018510191A5 JP2018510191A5 JP2017551589A JP2017551589A JP2018510191A5 JP 2018510191 A5 JP2018510191 A5 JP 2018510191A5 JP 2017551589 A JP2017551589 A JP 2017551589A JP 2017551589 A JP2017551589 A JP 2017551589A JP 2018510191 A5 JP2018510191 A5 JP 2018510191A5
- Authority
- JP
- Japan
- Prior art keywords
- tautomers
- solvates
- stereoisomers
- salts
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 18
- 239000012453 solvate Substances 0.000 claims 18
- -1 3-difluoromethoxy-5-fluoropyridin-4-yl Chemical group 0.000 claims 15
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 5
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 claims 4
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 claims 4
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 206010027476 Metastases Diseases 0.000 claims 3
- 239000002168 alkylating agent Substances 0.000 claims 2
- 229940100198 alkylating agent Drugs 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 2
- 150000003058 platinum compounds Chemical class 0.000 claims 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 1
- 206010024305 Leukaemia monocytic Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 241000507627 Salana Species 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 208000035474 group of disease Diseases 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 210000004324 lymphatic system Anatomy 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000006894 monocytic leukemia Diseases 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15000968.6 | 2015-04-02 | ||
| EP15000968 | 2015-04-02 | ||
| PCT/EP2016/000542 WO2016155884A1 (de) | 2015-04-02 | 2016-03-31 | Imidazolonylchinoline und deren verwendung als atm kinase inhibitoren |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020185129A Division JP7111790B2 (ja) | 2015-04-02 | 2020-11-05 | イミダゾロニルキノリンおよびａｔｍキナーゼ阻害剤としてのその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018510191A JP2018510191A (ja) | 2018-04-12 |
| JP2018510191A5 true JP2018510191A5 (enExample) | 2019-05-16 |
| JP6791873B2 JP6791873B2 (ja) | 2020-11-25 |
Family
ID=52814780
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017551589A Active JP6791873B2 (ja) | 2015-04-02 | 2016-03-31 | イミダゾロニルキノリンおよびａｔｍキナーゼ阻害剤としてのその使用 |
| JP2020185129A Active JP7111790B2 (ja) | 2015-04-02 | 2020-11-05 | イミダゾロニルキノリンおよびａｔｍキナーゼ阻害剤としてのその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020185129A Active JP7111790B2 (ja) | 2015-04-02 | 2020-11-05 | イミダゾロニルキノリンおよびａｔｍキナーゼ阻害剤としてのその使用 |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US10457677B2 (enExample) |
| EP (3) | EP3277681B1 (enExample) |
| JP (2) | JP6791873B2 (enExample) |
| KR (2) | KR102652052B1 (enExample) |
| CN (3) | CN107889488B (enExample) |
| AU (4) | AU2016239270B2 (enExample) |
| BR (1) | BR122019005502B1 (enExample) |
| DK (2) | DK3277681T3 (enExample) |
| ES (3) | ES2880626T3 (enExample) |
| HR (2) | HRP20191396T1 (enExample) |
| HU (2) | HUE054745T2 (enExample) |
| IL (3) | IL254714B (enExample) |
| LT (2) | LT3560924T (enExample) |
| MX (2) | MX376947B (enExample) |
| PL (2) | PL3560924T3 (enExample) |
| PT (2) | PT3560924T (enExample) |
| RS (2) | RS59139B1 (enExample) |
| RU (1) | RU2743343C2 (enExample) |
| SG (2) | SG11201708065QA (enExample) |
| SI (2) | SI3277681T1 (enExample) |
| TR (1) | TR201911244T4 (enExample) |
| WO (1) | WO2016155884A1 (enExample) |
| ZA (1) | ZA201707423B (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10457677B2 (en) * | 2015-04-02 | 2019-10-29 | Merck Patent Gmbh | Imidazolonylquinolines and the use thereof as ATM kinase inhibitors |
| GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
| GB201519406D0 (en) * | 2015-11-03 | 2015-12-16 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
| CN110312717B (zh) * | 2017-02-27 | 2022-04-12 | 上海瑛派药业有限公司 | 取代的稠合杂芳三环化合物作为激酶抑制剂及其应用 |
| JOP20190209A1 (ar) * | 2017-03-16 | 2019-09-12 | Astrazeneca Ab | مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان |
| CN111587126A (zh) | 2018-01-12 | 2020-08-25 | 普罗林科斯有限责任公司 | 组合剂型和用于验证的造影剂毒性最小化方案 |
| AU2019233596A1 (en) * | 2018-03-14 | 2020-10-08 | Merck Patent Gmbh | Compounds and uses thereof to treat tumors in a subject |
| EP3904349B1 (en) | 2018-04-12 | 2023-08-23 | Bayer Aktiengesellschaft | N-(cyclopropylmethyl)-5-(methylsulfonyl)-n-{1-[1-(pyrimidin-2-yl)-1h-1,2,4-triazol-5-yl]ethyl}heterocyclyl amide derivatives and similar compounds as pesticides |
| WO2019201283A1 (en) * | 2018-04-20 | 2019-10-24 | Xrad Therapeutics, Inc. | Dual atm and dna-pk inhibitors for use in anti-tumor therapy |
| CN110386932A (zh) * | 2018-04-20 | 2019-10-29 | 艾科思莱德制药公司 | 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂 |
| GB201814487D0 (en) * | 2018-09-06 | 2018-10-24 | Cycle Pharmaceuticals Ltd | Cancer |
| CN109045042A (zh) * | 2018-09-21 | 2018-12-21 | 上海交通大学医学院附属上海儿童医学中心 | Atm抑制剂在制备抑制急性淋巴细胞性白血病复发的药物中的应用 |
| AU2019348132B2 (en) * | 2018-09-30 | 2022-03-31 | Medshine Discovery Inc. | Quinolino-pyrrolidin-2-one derivative and application thereof |
| LT3947375T (lt) | 2019-03-27 | 2024-06-10 | Merck Patent Gmbh | Imidazolonilchinolino junginiai ir jų terapinis panaudojimas |
| WO2021022078A1 (en) * | 2019-07-30 | 2021-02-04 | Xrad Therapeutics, Inc. | Dual atm and dna-pk inhibitors for use in anti-tumor therapy |
| KR20220095205A (ko) * | 2019-11-01 | 2022-07-06 | 아레스 트레이딩 에스.아. | 암의 치료를 위한 방사선요법과 PD-1, TGFβ 및 ATM의 조합 억제 |
| AU2020398215A1 (en) * | 2019-12-04 | 2022-06-16 | Chdi Foundation, Inc. | ATM kinase inhibitors and compositions and methods of use thereof |
| CN115003672A (zh) * | 2020-01-09 | 2022-09-02 | 南京明德新药研发有限公司 | 喹啉并咪唑类化合物及其应用 |
| WO2021197339A1 (zh) * | 2020-03-30 | 2021-10-07 | 南京明德新药研发有限公司 | 作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用 |
| US20230226041A1 (en) * | 2020-06-18 | 2023-07-20 | Merck Patent Gmbh | Compounds for the treatment of viral infections |
| WO2021260580A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and atm inhibitor |
| CA3190226A1 (en) | 2020-09-18 | 2022-03-24 | Merck Patent Gmbh | Pharmaceutical preparation |
| WO2022060377A1 (en) * | 2020-09-21 | 2022-03-24 | Wei Zhong | Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one compounds with blood-brain barrier penetrable capability |
| EP3992191A1 (en) | 2020-11-03 | 2022-05-04 | Deutsches Krebsforschungszentrum | Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors |
| CN115232122B (zh) * | 2021-04-23 | 2024-05-31 | 石药集团中奇制药技术（石家庄）有限公司 | 炔类化合物及其制备和应用 |
| CN115716829B (zh) * | 2022-11-13 | 2024-05-31 | 药康众拓(江苏)医药科技有限公司 | 一种喹啉并咪唑酮联氘代吡唑类化合物及其应用 |
| KR20250112837A (ko) | 2022-11-23 | 2025-07-24 | 포워드 테라퓨틱스, 인코포레이티드 | TNF-α 활성의 조절제 |
| WO2025157979A1 (en) | 2024-01-26 | 2025-07-31 | Merck Patent Gmbh | Synthesis route for preparing 8-(1,3-dimethyl-1h-pyrazol-4-yl)-1-(sa)-(3-fluoro-5-methoxy-pyridin-4-yl)-7-methoxy-3-methyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-one |
| WO2025212627A1 (en) | 2024-04-03 | 2025-10-09 | Forward Therapeutics, Inc. | Modulators of tnf-alpha activity |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| DE60001623T2 (de) * | 1999-12-03 | 2003-12-18 | Pfizer Products Inc., Groton | Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel |
| GB0211649D0 (en) | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
| PL1879893T3 (pl) * | 2005-03-21 | 2010-11-30 | Ferrer Int | Sposób otrzymywania podstawionych w pozycji 1, związków 1H-imidazo[4,5-c]chinolino-4-aminowych i związki pośrednie |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| EP1934201A1 (en) * | 2005-10-06 | 2008-06-25 | Auspex Pharmaceuticals Inc. | Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties |
| US7750168B2 (en) * | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| BRPI0807893A2 (pt) | 2007-02-20 | 2014-06-17 | Novartis Ag | Imidazoquinolinas como inibidores duais de lipídio quinase e mtor. |
| CA2925257C (en) | 2008-03-26 | 2019-04-30 | Carlos Garcia-Echeverria | 5imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes |
| CA3000973A1 (en) | 2008-06-10 | 2009-12-17 | Abbvie Inc. | Tricyclic compounds |
| CN102170873B (zh) | 2008-10-01 | 2014-07-30 | 诺华股份有限公司 | 用于治疗与hedgehog通路有关的病症的smoothened拮抗 |
| US8476294B2 (en) | 2009-06-04 | 2013-07-02 | Novartis Ag | 1H-imidazo[4,5-c]quinolinone derivatives |
| JP2012528829A (ja) | 2009-06-04 | 2012-11-15 | ノバルティス アーゲー | １Ｈ−イミダゾ［４，５−ｃ］キノリノン化合物 |
| GB0919423D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| EA201201289A1 (ru) * | 2010-03-16 | 2013-08-30 | Мерк Патент Гмбх | Морфолинилхиназолины |
| SG186855A1 (en) * | 2010-06-28 | 2013-02-28 | Merck Patent Gmbh | 2,4- diaryl - substituted [1,8] naphthyridines as kinase inhibitors for use against cancer |
| CN102372711B (zh) | 2010-08-18 | 2014-09-17 | 山东轩竹医药科技有限公司 | 咪唑并喹啉类PI3K和mTOR双重抑制剂 |
| DE102010035744A1 (de) | 2010-08-28 | 2012-03-01 | Merck Patent Gmbh | Imidazolonylchinoline |
| CN102399218A (zh) | 2010-09-16 | 2012-04-04 | 和记黄埔医药（上海）有限公司 | 一类并合三杂环及其作为pi3k抑制剂的用途 |
| WO2012075253A2 (en) | 2010-12-03 | 2012-06-07 | Novartis Ag | Pharmaceutical compositions |
| CN103012398B (zh) | 2011-09-19 | 2015-10-14 | 上海恒瑞医药有限公司 | 咪唑并喹啉类衍生物及其可药用盐、其制备方法及其在医药上的应用 |
| US9879003B2 (en) | 2012-04-11 | 2018-01-30 | Dana-Farber Cancer Institute, Inc. | Host targeted inhibitors of dengue virus and other viruses |
| WO2013184621A1 (en) | 2012-06-06 | 2013-12-12 | Novartis Ag | Combination of a 17 -alpha -hydroxylase (c17, 20 - lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease |
| NO2714752T3 (enExample) * | 2014-05-08 | 2018-04-21 | ||
| US10457677B2 (en) | 2015-04-02 | 2019-10-29 | Merck Patent Gmbh | Imidazolonylquinolines and the use thereof as ATM kinase inhibitors |
-
2016
- 2016-03-31 US US15/563,680 patent/US10457677B2/en active Active
- 2016-03-31 EP EP16717560.3A patent/EP3277681B1/de active Active
- 2016-03-31 SI SI201630345T patent/SI3277681T1/sl unknown
- 2016-03-31 HR HRP20191396 patent/HRP20191396T1/hr unknown
- 2016-03-31 PL PL19172903T patent/PL3560924T3/pl unknown
- 2016-03-31 AU AU2016239270A patent/AU2016239270B2/en active Active
- 2016-03-31 RU RU2017138100A patent/RU2743343C2/ru active
- 2016-03-31 SG SG11201708065QA patent/SG11201708065QA/en unknown
- 2016-03-31 EP EP19172903.7A patent/EP3560924B1/de active Active
- 2016-03-31 DK DK16717560.3T patent/DK3277681T3/da active
- 2016-03-31 PT PT191729037T patent/PT3560924T/pt unknown
- 2016-03-31 CN CN201680031887.8A patent/CN107889488B/zh active Active
- 2016-03-31 RS RS20190993A patent/RS59139B1/sr unknown
- 2016-03-31 SI SI201631240T patent/SI3560924T1/sl unknown
- 2016-03-31 PT PT16717560T patent/PT3277681T/pt unknown
- 2016-03-31 DK DK19172903.7T patent/DK3560924T3/da active
- 2016-03-31 JP JP2017551589A patent/JP6791873B2/ja active Active
- 2016-03-31 ES ES19172903T patent/ES2880626T3/es active Active
- 2016-03-31 LT LTEP19172903.7T patent/LT3560924T/lt unknown
- 2016-03-31 RS RS20210817A patent/RS62082B1/sr unknown
- 2016-03-31 MX MX2017012613A patent/MX376947B/es active IP Right Grant
- 2016-03-31 HU HUE19172903A patent/HUE054745T2/hu unknown
- 2016-03-31 CN CN202010644109.4A patent/CN111747952A/zh active Pending
- 2016-03-31 BR BR122019005502-5A patent/BR122019005502B1/pt active IP Right Grant
- 2016-03-31 KR KR1020177031770A patent/KR102652052B1/ko active Active
- 2016-03-31 ES ES16717560T patent/ES2741853T3/es active Active
- 2016-03-31 ES ES21165573T patent/ES2946507T3/es active Active
- 2016-03-31 TR TR2019/11244T patent/TR201911244T4/tr unknown
- 2016-03-31 MX MX2020011558A patent/MX390537B/es unknown
- 2016-03-31 KR KR1020247009513A patent/KR20240044525A/ko active Pending
- 2016-03-31 EP EP21165573.3A patent/EP3868761B1/de active Active
- 2016-03-31 SG SG10202002181UA patent/SG10202002181UA/en unknown
- 2016-03-31 WO PCT/EP2016/000542 patent/WO2016155884A1/de not_active Ceased
- 2016-03-31 CN CN202010644289.6A patent/CN111689963A/zh active Pending
- 2016-03-31 HU HUE16717560A patent/HUE045477T2/hu unknown
- 2016-03-31 PL PL16717560T patent/PL3277681T3/pl unknown
- 2016-03-31 LT LTEP16717560.3T patent/LT3277681T/lt unknown
-
2017
- 2017-09-26 IL IL254714A patent/IL254714B/en active IP Right Grant
- 2017-11-01 ZA ZA2017/07423A patent/ZA201707423B/en unknown
-
2019
- 2019-03-14 US US16/353,559 patent/US10745399B2/en active Active
- 2019-12-17 IL IL271494A patent/IL271494B/en active IP Right Grant
-
2020
- 2020-06-24 US US16/910,438 patent/US10975075B2/en active Active
- 2020-06-25 AU AU2020204241A patent/AU2020204241B2/en active Active
- 2020-11-05 JP JP2020185129A patent/JP7111790B2/ja active Active
-
2021
- 2021-03-17 US US17/204,619 patent/US11608338B2/en active Active
- 2021-04-22 IL IL282584A patent/IL282584B/en unknown
- 2021-06-23 HR HRP20210981TT patent/HRP20210981T1/hr unknown
-
2022
- 2022-10-21 AU AU2022256215A patent/AU2022256215A1/en not_active Abandoned
-
2023
- 2023-03-01 US US18/116,094 patent/US20230203034A1/en active Pending
-
2025
- 2025-01-20 AU AU2025200385A patent/AU2025200385A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018510191A5 (enExample) | ||
| CN111214471B (zh) | 药物组合物及其用途 | |
| RU2010128107A (ru) | Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp | |
| JP2015096544A5 (enExample) | ||
| JPWO2019191470A5 (enExample) | ||
| ES2717898T3 (es) | Efecto potenciador para agentes antitumorales | |
| JP2019501204A5 (enExample) | ||
| JP2016528162A5 (enExample) | ||
| JP2013544846A5 (enExample) | ||
| JP2010528995A5 (enExample) | ||
| JP2019535746A5 (enExample) | ||
| JP2016501221A5 (enExample) | ||
| NZ580009A (en) | Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer | |
| JP2015515961A5 (enExample) | ||
| JP2020097596A5 (enExample) | ||
| RU2014154009A (ru) | Комбинация ингибитора 17-альфа-гидроксилазы (с17,20-лиазы) и специфического ингибитора pi-3k для лечения онкологического заболевания | |
| JP2011510028A5 (enExample) | ||
| JP2018062523A5 (enExample) | ||
| ES2945865T3 (es) | Combinación de un derivado de 6-oxo-1,6-dihidropiridazina que tiene actividad anticancerígena con un derivado de quinazolina | |
| JP2015519347A5 (enExample) | ||
| JP2017530154A5 (enExample) | ||
| JP6422936B2 (ja) | ５−ブロモ−インジルビン | |
| JP2014530181A5 (enExample) | ||
| JP4852605B2 (ja) | 放射線治療増強剤 | |
| ES2685974T3 (es) | Derivados de cefalosporina para tratar el cáncer |